NOT-CA-18-036: Notice of Correction to RFA-CA-18-010, "Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)"

Notice of Correction to RFA-CA-18-010, "Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)"

Notice Number: NOT-CA-18-036

Key Dates
Release Date: March 2, 2018

Related Announcements
RFA-CA-18-010

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct Part 2. Full Text of Announcement, Section IV. Application and Submission Information, 2. Content and Form of Application Submission, PHS 398 Research Plan (Research Project), Letters of Support, in RFA-CA-18-010, "Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)".

Part 2. Full Text of Announcement
Section IV. Application and Submission Information
2. Content and Form of Application Submission

PHS 398 Research Plan

Currently reads:

Letters of Support: If the revision application does not include the PD/PI for the parent U54 award, a letter of support must be included from the PD/PI for the parent U54 award.

Should correctly read (in italics):

Letters of Support: If the revision application does not include the PD/PI for the parent P50 award, a letter of support must be included from the PD/PI for the parent P50 award.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Tony Dickherber, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-547-9980
Email: [email protected]